Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Millendo Therapeutics Inc (MLND)

1.94   -0.13 (-6.28%) 03-03 17:03
Open: 2.09 Pre. Close: 2.07
High: 2.12 Low: 1.94
Volume: 752,156 Market Cap: 37M
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.124 - 2.136 2.136 - 2.149
Low: 1.908 - 1.921 1.921 - 1.934
Close: 1.917 - 1.938 1.938 - 1.962

Technical analysis

as of: 2021-03-03 4:42:56 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.82     One year: 3.24
Support: Support1: 1.85    Support2: 1.54
Resistance: Resistance1: 2.42    Resistance2: 2.77
Pivot: 2.38
Moving Average: MA(5): 2.09     MA(20): 2.37
MA(100): 1.92     MA(250): 2.20
MACD: MACD(12,26): -0.01     Signal(9): 0.07
Stochastic oscillator: %K(14,3): 9.96     %D(3): 11.93
RSI: RSI(14): 38.34
52-week: High: 8.42  Low: 1.26  Change(%): -76.3
Average Vol(K): 3-Month: 67636  10-Days: 48377

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
MLND has closed above bottom band by 6.2%. Bollinger Bands are 82.7% wider than normal. The large width of the bands suggest high volatility as compared to MLND's normal range. The bands have been in this wide range for 3 bars. This is a sign that the current trend might continue.

Headline News

Tue, 09 Feb 2021
Millendo Therapeutics - Consensus Indicates Potential 77.8% Upside - DirectorsTalk Interviews

Wed, 03 Feb 2021
Is Millendo Therapeutics Inc (MLND) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Mon, 01 Feb 2021
What is the Market's View on Millendo Therapeutics Inc (MLND) Stock's Price and Volume Trends - InvestorsObserver

Fri, 29 Jan 2021
How Does Millendo Therapeutics Inc (MLND) Stock Rank on Wall Street? - InvestorsObserver

Wed, 06 Jan 2021
Should You Buy Millendo Therapeutics Inc (MLND) Stock After it Is Lower By 20.00% in a Week? - InvestorsObserver

Tue, 05 Jan 2021
Analyst Rating: Will Millendo Therapeutics Inc (MLND) Stock Outperform the Market? - InvestorsObserver

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 19
Shares Float (M) 15
% Held by Insiders 6.29
% Held by Institutions 41.79
Shares Short (K) 703
Shares Short P. Month (K) 404

Stock Financials

EPS -2.348
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 2.060
Profit Margin
Operating Margin
Return on Assets (ttm) -48.5
Return on Equity (ttm) -98.6
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -2.183
Qtrly Earnings Growth
Operating Cash Flow (M) -37
Levered Free Cash Flow (M) -19

Stock Valuations

PE Ratio -0.83
PEG Ratio
Price to Book value 0.94
Price to Sales
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.